Comment
Author: Admin | 2025-04-28
We're on the right track, and so we want to make sure that it's additive to that. So that's the answer to your second question, David, and appreciate your questions.OperatorThank you. Our next question comes from Jason Gerberry of Bank of America. Your line is now open. Please go ahead.Jason Gerberry -- Analyst Hey, guys. Thank you for taking my questions. First one is just on generic Revlimid. It's clearly a big contributor from what I can gather. And so how should investors think about the sort of size of this product? They're going to need to model, this is revenue that will need to be replaced in 2026 when the limited competition dynamics come to an end. And along those lines, I'm seeing like in the first half, non-GAAP adjustments of about $270 million for contingent considerations on future royalties tied to generic Revlimid. So can you talk to the accounting on that? Is that just sort of a planned future royalties over the next year and a half while the product is subject to limited competition? So those are my questions. Thanks.Richard Francis -- President and Chief Executive Officer OK. Jason, thanks for the question. I'll start and maybe give Eli a chance to also contribute, so you don't have to just continuously listen to me talk. So we're pleased about -- firstly, let me just say we're pleased about our generics business, 14% growth globally. And we have a big business, as I've mentioned many times in the past in Europe and international, and that's growing at 8% and 22%. So really proud of that, and congratulations to the team. And I want to make sure we appreciate that. Now moving on to the U.S., which obviously we saw significant growth. Now part of that is driven by Revlimid, the continued good performance there. But I do want to remind everybody that we have launched a number of complex generics into the market this year, and that also drives growth as well as we launched Victoza in Q2. And obviously, Victoza is an exciting opportunity, the first GLP-1 into the market. And so that's received a lot of attention. And so also that's helping us drive growth. We also do have just underlying good performance in our generics business as we manage our supply chain better than we've done in the past. So I think all those fundamentals are together. Now we are aware that the Revlimid, there is going to come a point where this does come to an end. And because of that, we're focusing really hard on making sure we bring high-value complex direct to the market on time more often. And I think
Add Comment